Brain cancer experts explain the current wave of surgical advances and advocate for team-based, multidisciplinary strategies to individualize patient care.
|Articles|February 16, 2021
Supplements and Featured Publications
- Current and Emerging Trends in Chronic Myeloid Leukemia
- Volume 1
- Issue 1
Current and Future Trends in Chronic Myeloid Leukemia
Advertisement
This publication includes a summary of data on therapeutic agents for the current and future treatment landscape of chronic myeloid leukemia. Hematologic oncology experts provide key insights on approaching disease management, including a discussion on treatment options through later-line settings.
Articles in this issue
over 5 years ago
Dr. Cortes on the Future of Ponatinib in CML Treatmentover 5 years ago
Dr. Hobbs on Managing Ponatinib-Associated Toxicities in CMLover 5 years ago
Dr. Sweet on Treatment Selection With TKIs in CMLAdvertisement
Related to this article
GLP-1 receptor agonists are generating buzz for their metabolic benefits, as well as for their potential to directly combat breast cancer progression.
During a recent OncLive Peer Exchange, panelists discussed testing strategies, updated data, and treatment sequencing in ROS1+ NSCLC.
Aaron Gerds, MD, outlines how cytopenias affect patients with myelofibrosis and how these can help drive JAK inhibitor selection.
The MAPKeeper-301 trial is evaluating frontline atebimetinib plus chemotherapy vs standard chemotherapy in metastatic pancreatic ductal adenocarcinoma.
The ASPEN-09-03 trial is evaluating evorpacept plus trastuzumab and chemotherapy in previously treated HER2-positive metastatic breast cancer.
Philip A. Philip, MD, discusses TTFields, the recent approval of this modality in pancreatic cancer, and phase 3 data in locally advanced disease.
Focal therapy for prostate cancer has evolved over 2 decades, with advances in imaging, patient selection, treatment modalities, and clinical trials.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer
2
Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC
3
Daraxonrasib Yields Durable Responses in Previously Treated RAS-Mutant NSCLC
4
Novel Analysis Reveals Millions of Life-Years Saved by Blood Cancer Treatments
5